Lehigh Valley

Type: Teaching hospital
Where: ALLENTOWN, PA
Medicare CCN: 390133
Received: $3,606,348 in 476 records, 2020 ($186,262 general, $3,420,085 research)
Source: CMS Open Payments search ↗

On this site

Business registration: Lehigh Valley Corp. Fuzzy (name and state)

By year

Program year	Kind	Records	Amount
2020	General payment	143	$186,262
2020	Research payment	333	$3,420,085

By company

Company	Records	Amount	Years
E.R. Squibb & Sons, L.L.C.	53	$1,463,585	2020
PFIZER INC.	31	$472,009	2020
Karyopharm Therapeutics Inc.	16	$280,640	2020
Genentech, Inc.	18	$218,036	2020
Mallinckrodt Hospital Products Inc.	15	$181,397	2020
Merck Sharp & Dohme LLC	45	$139,162	2020
Medtronic Vascular, Inc.	34	$124,800	2020
Medtronic, Inc.	27	$116,332	2020
Boston Scientific Corporation	25	$116,306	2020
B. Braun Medical Inc.	3	$80,095	2020
SANOFI PASTEUR INC.	2	$69,115	2020
ABBVIE INC.	9	$36,891	2020
Diagnostica Stago, Inc	2	$35,773	2020
Hoffmann-La Roche Limited	7	$25,209	2020
Penumbra, Inc.	9	$21,650	2020
Gilead Sciences, Inc.	3	$21,650	2020
Incyte Corporation	14	$17,326	2020
Artivion, Inc.	2	$17,000	2020
Foundation Medicine, Inc.	5	$16,500	2020
Biogen, Inc.	3	$16,350	2020
Janssen Research & Development, LLC	3	$12,591	2020
W. L. Gore & Associates, Inc.	7	$11,035	2020
AstraZeneca Pharmaceuticals LP	5	$10,252	2020
Aesculap, Inc.	11	$9,122	2020
CSL Behring	13	$7,916	2020
Linvatec Corporation	2	$7,023	2020
Lilly USA, LLC	4	$6,500	2020
Sterilmed, Inc.	21	$6,134	2020
Medical Device Business Services, Inc.	4	$5,400	2020
Abbott Laboratories	7	$4,532	2020
Smith+Nephew, Inc.	1	$3,895	2020
HOLOGIC INC	1	$3,655	2020
Medtronic USA, Inc.	3	$3,450	2020
Zimmer Biomet Holdings, Inc.	1	$3,356	2020
SEAGEN INC.	7	$3,250	2020
ACADIA Pharmaceuticals Inc	1	$3,000	2020
Amgen Inc.	7	$2,750	2020
Bolton Medical Inc	3	$2,333	2020
Biom'Up France SAS	1	$2,000	2020
Medline Industries LP	2	$2,000	2020
Alexion Pharmaceuticals, Inc.	3	$1,750	2020
Eli Lilly and Company	1	$1,700	2020
Becton, Dickinson and Company	2	$1,600	2020
Allergan, Inc.	2	$1,500	2020
Varian Medical Systems, Inc.	1	$1,500	2020
GRT US Holding, Inc.	1	$1,500	2020
Stryker Corporation	3	$1,419	2020
Eisai Inc.	3	$1,250	2020
Astellas Pharma US Inc	3	$1,250	2020
Ipsen Biopharmaceuticals, Inc	3	$1,250	2020

By nature of payment

Nature	Records	Amount
Research payment	333	$3,420,085
Charitable Contribution	9	$98,536
Space rental or facility fees (teaching hospital only)	70	$29,224
Grant	14	$21,429
Gift	15	$16,889
Education	10	$11,799
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	24	$6,884
Consulting Fee	1	$1,500

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2020-12-31	Zimmer Biomet Holdings, Inc.	$3,356	Gift	In-kind items and services	Zimmer Biomet Instruments and Implants Device, General		2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$1,267	Research payment	In-kind items and services	EPANOVA Drug, Cardiovascular and Metabolism	A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi	2020
2020-12-31	Linvatec Corporation	$658	Grant	In-kind items and services	HALL POWER Device, ORTHOPEDIC SURGERY		2020
2020-12-31	Siemens Medical Solutions USA, Inc.	$36	Charitable Contribution	In-kind items and services			2020
2020-12-23	E.R. Squibb & Sons, L.L.C.	$500	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase III RCC 1L Combo	2020
2020-12-23	Foundation Medicine, Inc.	$500	Charitable Contribution	Cash or cash equivalent			2020
2020-12-21	Artivion, Inc.	$4,500	Research payment	Cash or cash equivalent	On-X Device, Cardiology and Vascular Diseases	ON-X Aortic Prosthetic Heart Valve: Low dose Warfarin Post Approval Clinical Registry Study (PAS)	2020
2020-12-18	PFIZER INC.	$3,945	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-12-18	Genentech, Inc.	$3,067	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	NEOADJUVANT NSCLC	2020
2020-12-18	Genentech, Inc.	$780	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	NEOADJUVANT NSCLC	2020
2020-12-18	Medtronic Vascular, Inc.	$500	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	Optimize Pro	2020
2020-12-18	Sterilmed, Inc.	$482	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-12-17	Medtronic Vascular, Inc.	$3,741	Research payment	Cash or cash equivalent	Viva Device, Implantable Cardioverter Defibrillators (ICDs)	AdaptResponse	2020
2020-12-17	PFIZER INC.	$1,500	Research payment	Cash or cash equivalent	BAVENCIO Drug, ONCOLOGY	A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS	2020
2020-12-17	Penumbra, Inc.	$1,240	Research payment	Cash or cash equivalent	Indigo Device, Peripheral Intervention	CHEETAH	2020
2020-12-15	Hoffmann-La Roche Limited	$1,459	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE	2020
2020-12-14	Linvatec Corporation	$6,364	Grant	In-kind items and services	HALL POWER Device, ORTHOPEDIC SURGERY		2020
2020-12-11	PFIZER INC.	$5,502	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-12-10	Medtronic, Inc.	$16,545	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-12-10	Aesculap, Inc.	$5,397	Gift	Cash or cash equivalent			2020
2020-12-10	Genentech, Inc.	$1,500	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	2020
2020-12-10	Aesculap, Inc.	$1,349	Gift	Cash or cash equivalent			2020
2020-12-10	Medtronic, Inc.	$1,128	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-12-10	Aesculap, Inc.	$723	Gift	Cash or cash equivalent			2020
2020-12-10	Medtronic, Inc.	$620	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-12-10	Aesculap, Inc.	$566	Gift	Cash or cash equivalent			2020
2020-12-10	Medtronic, Inc.	$542	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-12-10	E.R. Squibb & Sons, L.L.C.	$500	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase IIA 2L Prostate Ipi Nivo Combo	2020
2020-12-10	Medtronic, Inc.	$340	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-12-10	Medtronic, Inc.	$292	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-12-10	Medtronic, Inc.	$289	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-12-10	Aesculap, Inc.	$227	Gift	Cash or cash equivalent			2020
2020-12-10	Aesculap, Inc.	$186	Gift	Cash or cash equivalent			2020
2020-12-10	Aesculap, Inc.	$174	Gift	Cash or cash equivalent			2020
2020-12-10	Aesculap, Inc.	$127	Gift	Cash or cash equivalent			2020
2020-12-10	Aesculap, Inc.	$127	Gift	Cash or cash equivalent			2020
2020-12-10	Aesculap, Inc.	$127	Gift	Cash or cash equivalent			2020
2020-12-10	Aesculap, Inc.	$113	Gift	Cash or cash equivalent			2020
2020-12-09	Medtronic, Inc.	$7,890	Research payment	Cash or cash equivalent			2020
2020-12-08	Karyopharm Therapeutics Inc.	$33,467	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-12-08	ABBVIE INC.	$10,800	Research payment	In-kind items and services	VENCLEXTA Drug, ONCOLOGY	C19-920	2020
2020-12-08	ABBVIE INC.	$9,000	Research payment	In-kind items and services	VENCLEXTA Drug, ONCOLOGY	C19-920	2020
2020-12-08	ABBVIE INC.	$5,400	Research payment	In-kind items and services	VENCLEXTA Drug, ONCOLOGY	C19-920	2020
2020-12-08	Karyopharm Therapeutics Inc.	$2,000	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-12-06	Eisai Inc.	$500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Lenvima Drug, Oncology		2020
2020-12-04	PFIZER INC.	$4,840	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-12-03	HOLOGIC INC	$3,655	Grant	In-kind items and services	Securview Device, Breast and Skeletal Health		2020
2020-12-02	GE HEALTHCARE	$699	Education	Cash or cash equivalent			2020
2020-12-02	Medtronic Vascular, Inc.	$500	Research payment	Cash or cash equivalent	Reveal LINQ Device, Cardiac Diagnostics and Monitoring	Reveal LINQ Registry	2020
2020-12-01	Genentech, Inc.	$179,854	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	2020
2020-12-01	Genentech, Inc.	$903	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	2020
2020-11-30	Merck Sharp & Dohme LLC	$550	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax	2020
2020-11-26	Mallinckrodt Hospital Products Inc.	$35,287	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-11-26	PFIZER INC.	$8,015	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-11-26	Mallinckrodt Hospital Products Inc.	$500	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-11-25	E.R. Squibb & Sons, L.L.C.	$500	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase IIIB Dose Comparison N3 I1 vs I3 N1 in melanoma	2020
2020-11-25	Abbott Laboratories	$75	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2020
2020-11-24	E.R. Squibb & Sons, L.L.C.	$500	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase III NSCLC 1L, sq anti-PD-1 vs platinum doublet PDL-1	2020
2020-11-24	Hoffmann-La Roche Limited	$300	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE	2020
2020-11-24	Hoffmann-La Roche Limited	$150	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE	2020
2020-11-20	PFIZER INC.	$26,966	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-11-20	Merck Sharp & Dohme LLC	$1,200	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot	2020
2020-11-20	W. L. Gore & Associates, Inc.	$540	Research payment	Cash or cash equivalent	Product in Development Device, Devices	GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P	2020
2020-11-20	Genentech, Inc.	$500	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	NEOADJUVANT NSCLC	2020
2020-11-19	SANOFI PASTEUR INC.	$20,470	Research payment	Cash or cash equivalent		STA00011 Stamaril Yellow Fever	2020
2020-11-19	Penumbra, Inc.	$7,670	Research payment	Cash or cash equivalent	Indigo Device, Peripheral Intervention	CHEETAH	2020
2020-11-19	Hoffmann-La Roche Limited	$1,500	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE	2020
2020-11-18	Abbott Laboratories	$99	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2020
2020-11-17	Genentech, Inc.	$1,848	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	2020
2020-11-16	Boston Scientific Corporation	$5,288	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	INSIGHT ATP	2020
2020-11-14	PFIZER INC.	$32,381	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-11-12	CSL Behring	$764	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-11-12	Sterilmed, Inc.	$434	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-11-12	CSL Behring	$65	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-11-12	Sterilmed, Inc.	$17	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-11-06	PFIZER INC.	$21,472	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-11-05	E.R. Squibb & Sons, L.L.C.	$2,500	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase III Adjuvant Melanoma Stage II B C Opdivo Mono	2020
2020-10-30	PFIZER INC.	$3,855	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-10-29	Medtronic Vascular, Inc.	$4,387	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	TAVR Low Risk	2020
2020-10-29	Medtronic Vascular, Inc.	$4,387	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	TAVR Low Risk	2020
2020-10-29	E.R. Squibb & Sons, L.L.C.	$1,100	Research payment	Cash or cash equivalent	ELIQUIS Drug, Cardiovascular	Phase III VTE Prev with Children with ALL	2020
2020-10-29	PUMA BIOTECHNOLOGY, INC.	$1,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	NERLYNX Drug, ONCOLOGY		2020
2020-10-27	Medtronic Vascular, Inc.	$1,500	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	Optimize Pro	2020
2020-10-26	Smith+Nephew, Inc.	$3,895	Gift	In-kind items and services	TRIGEN Femoral (FAN/TAN/Meta Nail) Device, Trauma Plates, Screws, and Nails		2020
2020-10-23	Abbott Laboratories	$300	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2020
2020-10-22	PFIZER INC.	$89,015	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-10-22	Penumbra, Inc.	$2,470	Research payment	Cash or cash equivalent	Indigo Device, Peripheral Intervention	CHEETAH	2020
2020-10-21	Genentech, Inc.	$178	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	NEOADJUVANT NSCLC	2020
2020-10-20	CSL Behring	$1,000	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-10-20	CSL Behring	$1,000	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-10-19	Boston Scientific Corporation	$1,500	Research payment	Cash or cash equivalent	ACUITY Device, TACHY	NAVIGATE X4 STUDY	2020
2020-10-16	Medtronic Vascular, Inc.	$6,145	Research payment	Cash or cash equivalent	Viva Device, Implantable Cardioverter Defibrillators (ICDs)	AdaptResponse	2020
2020-10-16	Genentech, Inc.	$130	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	NEOADJUVANT NSCLC	2020
2020-10-15	Medtronic Vascular, Inc.	$2,567	Research payment	Cash or cash equivalent		ECG Belt	2020
2020-10-13	Merck Sharp & Dohme LLC	$2,500	Research payment	Cash or cash equivalent	V114 Biological, VACCINE	A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerabilit	2020
2020-10-09	PFIZER INC.	$38,511	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-10-08	PFIZER INC.	$6,965	Research payment	Cash or cash equivalent		A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST	2020
2020-10-08	PFIZER INC.	$366	Research payment	Cash or cash equivalent		A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST	2020
2020-10-07	Sterilmed, Inc.	$489	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-10-07	Sterilmed, Inc.	$87	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-10-06	Karyopharm Therapeutics Inc.	$7,730	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-10-06	Karyopharm Therapeutics Inc.	$302	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-10-05	Gilead Sciences, Inc.	$350	Research payment	Cash or cash equivalent	Veklury Drug, COVID-19	A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi	2020
2020-10-02	E.R. Squibb & Sons, L.L.C.	$2,500	Research payment	Cash or cash equivalent		Ph I II mono lag3 vs combo lag3 nivo solid tumors	2020
2020-10-01	PFIZER INC.	$59,991	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-09-30	Incyte Corporation	$2,326	Research payment	Cash or cash equivalent		Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S	2020
2020-09-28	Medtronic Vascular, Inc.	$1,500	Research payment	Cash or cash equivalent		ECG Belt	2020
2020-09-25	PFIZER INC.	$68,159	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-09-23	Merck Sharp & Dohme LLC	$19,541	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot	2020
2020-09-23	Medtronic Vascular, Inc.	$2,275	Research payment	Cash or cash equivalent	Reveal LINQ Device, Cardiac Diagnostics and Monitoring	Reveal LINQ Registry	2020
2020-09-22	Medtronic, Inc.	$2,574	Research payment	Cash or cash equivalent			2020
2020-09-21	Boston Scientific Corporation	$2,362	Research payment	Cash or cash equivalent	ACUITY Device, TACHY	NAVIGATE X4 STUDY	2020
2020-09-18	PFIZER INC.	$51,119	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-09-18	W. L. Gore & Associates, Inc.	$533	Research payment	Cash or cash equivalent	Product in Development Device, Devices	GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P	2020
2020-09-17	Medtronic, Inc.	$16,615	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-09-17	Medtronic, Inc.	$1,674	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-09-17	Medtronic, Inc.	$1,504	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-09-17	Genentech, Inc.	$614	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	NEOADJUVANT NSCLC	2020
2020-09-17	Karyopharm Therapeutics Inc.	$549	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-09-17	Medtronic, Inc.	$289	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-09-17	Medtronic, Inc.	$287	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-09-17	Medtronic, Inc.	$62	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-09-15	Medtronic Vascular, Inc.	$7,403	Research payment	Cash or cash equivalent	Viva Device, Implantable Cardioverter Defibrillators (ICDs)	AdaptResponse	2020
2020-09-11	Mallinckrodt Hospital Products Inc.	$65,393	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-09-11	Mallinckrodt Hospital Products Inc.	$11,137	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-09-11	PFIZER INC.	$4,868	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-09-11	Mallinckrodt Hospital Products Inc.	$1,500	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-09-11	Mallinckrodt Hospital Products Inc.	$215	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-09-11	Mallinckrodt Hospital Products Inc.	$215	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-09-11	Mallinckrodt Hospital Products Inc.	$215	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-09-11	Mallinckrodt Hospital Products Inc.	$215	Research payment	Cash or cash equivalent		A PHASE 2B/3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL OF VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN	2020
2020-09-10	Medtronic Vascular, Inc.	$276	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	Optimize Pro	2020
2020-09-09	Gilead Sciences, Inc.	$300	Research payment	Cash or cash equivalent	Veklury Drug, COVID-19	A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi	2020
2020-09-08	Boston Scientific Corporation	$11,936	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	INSIGHT ATP	2020
2020-09-05	PFIZER INC.	$5,500	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-09-03	Sterilmed, Inc.	$608	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-09-03	Sterilmed, Inc.	$140	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-08-26	Abbott Laboratories	$289	Research payment	Cash or cash equivalent	Optisure ICD Lead Device, Cardiac Arrhythmias and Heart Failure	Optisure Lead Post Approval Study	2020
2020-08-18	Karyopharm Therapeutics Inc.	$132,098	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-08-18	Karyopharm Therapeutics Inc.	$27,090	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-08-18	PFIZER INC.	$15,500	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-08-18	Artivion, Inc.	$12,500	Research payment	Cash or cash equivalent	On-X Device, Cardiology and Vascular Diseases	ON-X Aortic Prosthetic Heart Valve: Low dose Warfarin Post Approval Clinical Registry Study (PAS)	2020
2020-08-18	Karyopharm Therapeutics Inc.	$800	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-08-11	CSL Behring	$1,500	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-08-11	Merck Sharp & Dohme LLC	$1,000	Research payment	Cash or cash equivalent	V114 Biological, VACCINE	A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerabilit	2020
2020-08-11	CSL Behring	$657	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-08-11	CSL Behring	$65	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-08-10	Gilead Sciences, Inc.	$21,000	Research payment	Cash or cash equivalent	Veklury Drug, COVID-19	A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi	2020
2020-08-06	Merck Sharp & Dohme LLC	$58,625	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP	2020
2020-08-05	Merck Sharp & Dohme LLC	$6,450	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot	2020
2020-08-05	Sterilmed, Inc.	$279	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-08-05	Sterilmed, Inc.	$100	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-08-05	Sterilmed, Inc.	$51	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-08-04	Hoffmann-La Roche Limited	$4,800	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE	2020
2020-08-03	Hoffmann-La Roche Limited	$500	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE	2020
2020-07-30	Janssen Research & Development, LLC	$1,500	Research payment	Cash or cash equivalent		A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety 01F macitentan in su	2020
2020-07-23	Karyopharm Therapeutics Inc.	$4,370	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-07-17	E.R. Squibb & Sons, L.L.C.	$53,529	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase III NSCLC 1L, sq anti-PD-1 vs platinum doublet PDL-1	2020
2020-07-17	Medtronic Vascular, Inc.	$4,809	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	TAVR Low Risk	2020
2020-07-17	Medtronic Vascular, Inc.	$4,809	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	TAVR Low Risk	2020
2020-07-16	Penumbra, Inc.	$1,500	Research payment	Cash or cash equivalent	Indigo Device, Peripheral Intervention	CHEETAH	2020
2020-07-15	Medtronic Vascular, Inc.	$1,500	Research payment	Cash or cash equivalent	Viva Device, Implantable Cardioverter Defibrillators (ICDs)	AdaptResponse	2020
2020-07-14	Karyopharm Therapeutics Inc.	$12,500	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-07-14	Karyopharm Therapeutics Inc.	$3,500	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-07-14	Karyopharm Therapeutics Inc.	$2,000	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-07-14	Karyopharm Therapeutics Inc.	$2,000	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-07-14	Karyopharm Therapeutics Inc.	$1,500	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-07-14	Karyopharm Therapeutics Inc.	$1,500	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-07-14	Medtronic Vascular, Inc.	$816	Research payment	Cash or cash equivalent	Viva Device, Implantable Cardioverter Defibrillators (ICDs)	AdaptResponse	2020
2020-07-09	Merck Sharp & Dohme LLC	$1,500	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for	2020
2020-07-08	Merck Sharp & Dohme LLC	$13,000	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot	2020
2020-07-08	Bolton Medical Inc	$1,500	Research payment	Cash or cash equivalent	RelayPro Device, Device	RelayPro	2020
2020-07-08	Bolton Medical Inc	$500	Research payment	Cash or cash equivalent	RelayPro Device, Device	RelayPro	2020
2020-07-08	Bolton Medical Inc	$333	Research payment	Cash or cash equivalent	RelayPro Device, Device	RelayPro	2020
2020-07-07	E.R. Squibb & Sons, L.L.C.	$4,286	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemother	2020
2020-07-06	Boston Scientific Corporation	$9,065	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	INSIGHT ATP	2020
2020-07-01	Genentech, Inc.	$17,000	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	2020
2020-07-01	Genentech, Inc.	$2,050	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	2020
2020-07-01	Genentech, Inc.	$1,200	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	2020
2020-07-01	Genentech, Inc.	$1,000	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	2020
2020-06-30	Merck Sharp & Dohme LLC	$1,350	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca	2020
2020-06-26	W. L. Gore & Associates, Inc.	$3,874	Research payment	Cash or cash equivalent	Product in Development Device, Devices	GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P	2020
2020-06-26	W. L. Gore & Associates, Inc.	$1,500	Research payment	Cash or cash equivalent	Product in Development Device, Devices	GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P	2020
2020-06-25	Hoffmann-La Roche Limited	$16,500	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE	2020
2020-06-24	Sterilmed, Inc.	$174	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-06-23	Karyopharm Therapeutics Inc.	$49,234	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-06-23	Merck Sharp & Dohme LLC	$1,500	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax	2020
2020-06-22	Boston Scientific Corporation	$1,373	Research payment	Cash or cash equivalent	RESONATE Device, TACHY	PREEMPT HF	2020
2020-06-22	ABBVIE INC.	$624	Research payment	Cash or cash equivalent		M14-011	2020
2020-06-19	W. L. Gore & Associates, Inc.	$350	Research payment	Cash or cash equivalent	Product in Development Device, Devices	GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P	2020
2020-06-18	Sterilmed, Inc.	$1,152	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-06-18	Sterilmed, Inc.	$216	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-06-18	Sterilmed, Inc.	$209	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-06-18	Sterilmed, Inc.	$68	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-06-17	Medtronic, Inc.	$11,819	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-06-17	Medtronic, Inc.	$927	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-06-17	Medtronic, Inc.	$802	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-06-17	Medtronic, Inc.	$565	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-06-17	Medtronic, Inc.	$399	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020
2020-06-17	Medtronic, Inc.	$194	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2020

The latest 200 records of 476.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In Pennsylvania; placed by its state only.

Measure	State Pennsylvania
Population B01003	13,018,639
Population, 2020 census P1	13,002,700
Median age B01002	40.9
Under 18 B01001	20.4%
65 and over B01001	19.5%
Households B11001	5,274,853
Foreign born B05002	7.7%
Median household income B19013	$77,971
Median family income B19113	$100,262
Per capita income B19301	$44,355
Poverty rate B17001	11.7%
Unemployment rate B23025	5.3%
Civilian labor force B23025	6,684,175
Mean commute (minutes) B08013	26.3
Bachelor's degree or higher B15003	35.2%
Housing units B25001	5,806,452
Owner-occupied B25003	69.3%
Renters B25003	30.7%
Median home value B25077	$254,500
Median gross rent B25064	$1,209
White, not Hispanic B03002	73.0%
Black B03002	10.3%
Hispanic or Latino B03002	8.7%
Asian B03002	3.8%
American Indian and Alaska Native B03002	0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Pennsylvania.